BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AC Immune readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies AC Immune's drugs run\, from Clin
 icalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06544616-685@assetmemo.bio
DTSTAMP:20261121T005859Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:ACI-35.030: Phase 2 readout est. (NCT06544616)
DESCRIPTION:ACI-35.030\, phase 2\, Alzheimer's Disease.\nStudy: A Study of 
 JNJ-64042056 in Participants With Preclinical Alzheimer's Disease\nEstimat
 ed primary completion: 22 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/aci-35-030#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06544616
URL:https://assetmemo.bio/drug/aci-35-030#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06015841-1567@assetmemo.bio
DTSTAMP:20261121T005859Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:AFFITOPE PD01A / ACI-7104.056: Phase 2 readout est. (NCT06015841)
DESCRIPTION:AFFITOPE PD01A / ACI-7104.056\, phase 2\, Parkinson's Disease.\
 nStudy: A Study to Evaluate the Effects of ACI-7104.056 in Patients With E
 arly Stages of Parkinson's Disease\nEstimated primary completion: June 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/affitope-pd01a-aci
 -7104-056#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06015841
URL:https://assetmemo.bio/drug/affitope-pd01a-aci-7104-056#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05462106-680@assetmemo.bio
DTSTAMP:20261121T005859Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:ACI-24.060: Phase 1/2 readout est. (NCT05462106)
DESCRIPTION:ACI-24.060\, phase 1/2\, Alzheimer's Disease.\nStudy: A Study t
 o Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Synd
 rome (ABATE Study)\nEstimated primary completion: April 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/aci-24-060#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05462106
URL:https://assetmemo.bio/drug/aci-24-060#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
